Erasmus University Medical Center-ko ikertzaileekin lankidetzan egindako argitalpenak (15)

2024

  1. Event-free survival of maralixibat-treated patients with Alagille syndrome compared to a real-world cohort from GALA

    Hepatology (Baltimore, Md.), Vol. 79, Núm. 6, pp. 1279-1292

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

  3. Validation and optimization of AFP-based biomarker panels for early HCC detection in Latin America and Europe

    Hepatology Communications, Vol. 7, Núm. 10

2021

  1. Building consensus on definition and nomenclature of hepatic, pancreatic, and biliary organoids

    Cell Stem Cell, Vol. 28, Núm. 5, pp. 816-832

  2. Mapping the human genetic architecture of COVID-19

    Nature, Vol. 600, Núm. 7889, pp. 472-477

2020

  1. Cholangiocarcinoma 2020: the next horizon in mechanisms and management

    Nature Reviews Gastroenterology and Hepatology, Vol. 17, Núm. 9, pp. 557-588

2019

  1. Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy

    Leukemia and Lymphoma, Vol. 60, Núm. 5, pp. 1146-1155

2017

  1. Global position paper on cardiovascular regenerative medicine

    European Heart Journal

  2. Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition

    Oncogene, Vol. 36, Núm. 19, pp. 2737-2749

2016

  1. Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage

    Cancer Cell, Vol. 30, Núm. 5, pp. 806-821

2011

  1. Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy

    Haematologica, Vol. 96, Núm. 10, pp. 1470-1477

2010

  1. Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy

    Haematologica, Vol. 95, Núm. 3, pp. 424-431

2008

  1. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: Long-term outcome of the LPA 99 multicenter study by the PETHEMA Group

    Blood, Vol. 112, Núm. 8, pp. 3130-3134

2007

  1. Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia

    Nature Genetics, Vol. 39, Núm. 5, pp. 593-595